Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumour cells

# Interim Results for the six months ended 30 June 2024

Andrew Newland and Ian Griffiths

26 September 2024

LSE AIM:AGL

# Legal Disclaimer

This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be abound by the following conditions.

The presentation slides which follow this notice and the oral presentation of which it forms part (together, the “Materials") are personal to the recipient and have been prepared and issued by or on behalf of the Company. For the purposes of the remainder of this notice, the term Materials shall include the presentation, the question-and-answer session that follows the presentation, hard or electronic copies of this document and any other materials distributed at, or in connection with, the presentation. The recipient agrees to return all Materials held by it in relation to this presentation upon the Company's request.

The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this presentation and any errors therein or omissions therefrom.

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company’s nominated adviser, Joh. Berenberg, Gossler & Co. KG (London branch) (“Berenberg”) has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA") and accordingly it is a communication directed only at persons whose ordinary activities involve them acquiring, holding, managing and disposing of investments (as principal or agent) for the purposes of their business and who have professional experience in matters relating to investments and are (1) if in a member state of the European Economic Area (“EEA”), “Qualified Investors” as defined in Article 2(E) of Regulation (EU) 2017/1129 (the “EU Prospectus Regulation”) (“EU Qualified Investors”), (2) if in the United Kingdom, “Qualified Investors” as defined in Article 2(E) of the EU Prospectus Regulation, which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”) who (a) fall within one or more of the exemptions from section 21 of FSMA contained in the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) (“UK Qualified Investors”) or (3) persons to whom it may otherwise be lawful to communicate it (all such persons together being referred as "Relevant Persons"). Any investment or investment activity to which this document relates is only available to the Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to Berenberg or the Company immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA).

This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company’s financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as “anticipates”, “expects”, “should”, “intends”, “plans”, “believes”, “outlook”, “seeks”, “estimates”, “targets”, “may”, “will”, “continue”, “project” and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of the Company’s future performance and are subject to assumptions, risks and uncertainties that could cause actual future results to differ materially from those expressed in or implied by such forward-looking statements. No statement in the Materials is intended to be nor may it be construed as a profit forecast. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company’s ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Company's and its subsidiaries' (the "Group") research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group’s products by customers.

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors’ Report section including the “Principal Risks and Uncertainties” in the most recent Annual Report & Financial Statements of the Company. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.

# Large Pharma strategy in place

- Next generation blockbuster drugs need **companion diagnostics** (new classes of drugs: ADCs, DDR inhibitors, immunotherapy combinations)
- **Clonal evolution** of cancer critical to disease progression requires real-time non-invasive assessment (simple blood test)
- Large pharma need **competitive differentiation**, reduced trial costs, higher probability of trial success, increased likelihood of regulatory clearance, higher reimbursement pricing and better patient responses

***Better patient selection*** ***= better overall response rates***

***= higher reimbursement and wider adoption***

# First Half Highlights

## Half year

- **Three large Pharma contracts secured**
  - Eisai: HER2 breast cancer
  - AstraZeneca: DDR multiple cancers
  - AstraZeneca: AR prostate cancer
- **Breakthrough DNA results** demonstrating dual analysis of CTCs and ctDNA identifies key mutations not identified by ctDNA alone
- European and US patents on **CellKeep slide** designed to address endemic cell loss for microscope analysis
- Placing raising £9.3 million (gross) in June 2024

## Post period end

- **All three large pharma contracts progressing well** towards revenue expansion
- Fourth pharma services contract agreed with **Recursion Pharmaceuticals**
- **Exclusive deal for NGS DNA panel covering 6,500 mutations** in 61 clinically relevant genes for CTC and combined CTC and ctDNA analysis
- FDA regulation over LDTs constraining product sales
- **Prioritising investment in the growth of the large pharma strategy** to maximise ANGLE's commercial opportunity
- 100$^{th}$ peer reviewed publication

# Financial Results for the six months ended 30 June 2024

| | Six months ended 30 June 2024 £'000 | Six months ended 30 June 2023 £'000 | Year ended 31 December 2023 £'000 |
|---|---|---|---|
| **Statement of Comprehensive Income** | | | |
| Revenue | 1,034 | 1,196 | 2,186 |
| Cost of sales | (423) | (455) | (658) |
| Gross profit | 611 | 741 | 1,528 |
| Operating costs - cash | (7,500) | (8,619) | (17,871) |
| Operating costs - non-cash* | (1,414) | (2,756) | (5,416) |
| Tax credit and net finance costs | 590 | 821 | 1,627 |
| Loss for the period | (7,713) | (9,813) | (20,132) |
| Earnings per share (pence) | (2.89) | (3.77) | (7.73) |

| | 30 June2024 £'000 | 30 June2023 £'000 | 31 December 2023 £'000 |
|---|---|---|---|
| **Statement of Financial Position** | | | |
| Trade and other receivables and R&D tax credit | 3,977 | 5,111 | 3,319 |
| Inventories | 1,761 | 2,256 | 1,679 |
| Cash and cash equivalents | 17,882 | 22,162 | 16,218 |
| Property, plant and equipment and right-of-use assets | 6,703 | 7,887 | 7,226 |
| Intangible assets | 2,659 | 2,748 | 2,741 |
| Total assets | 32,982 | 40,164 | 31,183 |

*Share-based payments, depreciation, amortisation, unrealised FX on Group loans

## Highlights

- Planned operating expenditure (cash) of £7.5 million, reduced by 13%
- Cash position of £17.9 million
- Fundraise £8.6 million (net) June 2024
- R&D tax credit due £2.1 million (£1.5 million for FY23 due)

## Outlook

- Revenues for FY24 expected to be £3.0m to £3.7m
- Sold order book of up to £1.9 million at 30 June 2024
- Combined with a reduced cost base, the Company anticipates cashflow positive trading in the second half of 2026 and is funded to execute on this plan

# Large Pharma strategy revenue build

- Assay development and pilot studies c. £200,000

| ***Pharma companion diagnostic pathway - indicative only*** | | **Revenue Potential** |
|---|---|---|
| Year 1 | Phase 1 | £0.2m to £0.7m |
| Years 2-3 | Phase 2 | £1.2m to £3.6m |
| Years 4-5 | Phase 3 | £15m to £45m |
| Year 6 onwards | Companion Diagnostic | £20m to £100m per annum |

1. Potential for each project if fully progressed with all phases funded by pharma in pursuit of $multi-billion market per annum
2. Dependent on success of clinical trials and need for CDx to support regulatory clearance
3. Low development risk for ANGLE with exceptional potential

- Average cost of drug development in US is **US$285 million** with only 1 in 8 probability of achieving marketing authorisation[1]
- Average cost per patient in Phase 2 cancer trials **~ US$180,000**[1]
- Research suggests that Phase 2 success rates increase from 28% to 46% when a biomarker is used[2]

1. https://aspe.hhs.gov/reports/examination-clinical-trial-costs-barriers-drug-development-0
2. https://www.linkedin.com/pulse/biomarker-advantage-driving-trial-success-nda-group-ab/

# Eisai: HER2 breast cancer. ADC a new class of drug

There are 12 FDA approved ADCs as of January 2024[1] with two of these targeting HER2[2] and a further 140 HER2-ADCs in clinical development[1]



## Global Japanese pharma company

- Revenues >£3.7 billion[3] >10,000 employees
- >70 active oncology clinical trials >50,000 participants
- **HER2 targeting antibody-drug conjugate (ADC)** being co-developed by Eisai and Bliss Biopharmaceutical Co., Ltd as part of a US$2 billion investment
- ANGLE's HER2 assay to detect and assess HER2 low and HER2+ breast cancers in Phase 2 study
- Initial pilot study worth US$250,000
- Success in the pilot study offers the potential for multiple large scale follow-on studies
- Eisai seeking a HER2 CDx to support regulatory clearance and facilitate drug adoption worldwide

1. https://www.zs.com/insights/oncology-antibody-drug-conjugates-revolution
2. https://www.dana-farber.org/newsroom/features/antibody-drug-conjugates-cancer-therapy-revolution
3. Exchange rate as of 25 May 2024 where 1 JPY = 0.00500155 GBP, www.xe.com/ (accessed 25.05.2024 at 20:35)

# AstraZeneca: DDR multiple cancers

" It is through our **science-driven approach in targeting DDR mechanisms** that we have been able to contribute to **advances in precision medicine in oncology**.[2]"

**US$5.9 billion**
DDR therapeutics market value in 2022 and growing fast[3]

## Global pharma company with major oncology focus contributing to 39% of total product sales[1]

- 459 active, interventional cancer clinical trials in 139,000 patients
- Therapies targeting DNA Damage Response form one of six key scientific platforms for AstraZeneca
- ANGLE will develop methodology for CTC micronuclei detection using the company's **DNA Damage Response (DDR) assay**
- Six-month initial development phase worth c. £150,000
- CTCs provide a repeatable, minimally invasive means with which to potentially analyse DDR proteins to help understand the DDR pathway
- Could be used in clinical trials or the clinic to assess patient response to treatment

1. www.astrazeneca.com/content/dam/az/PDF/2023/fy/Full-year-and-Q4-2023-results-announcement.pdf
2. https://www.astrazeneca.com/our-therapy-areas/oncology/dna-damage-response.html
3. https://www.transparencymarketresearch.com/dna-repair-drugs-market.html

# AstraZeneca: AR prostate cancer

## Androgen Receptor (AR) detection assay for use in AstraZeneca's prostate cancer studies

- 12-month development phase worth £550,000
- ANGLE's AR assay could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up
- Potential for long-term ongoing business for ANGLE supporting AstraZeneca's prostate cancer clinical trials, with AstraZeneca seeking patent protection for a new class of AR drugs
- Wide applicability outside of AstraZeneca with 155 active, interventional oncology clinical studies in 39,000 participants including AR[1]

AR plays a pivotal role in prostate cancer, especially castration-resistant prostate cancer (CRPC).

CRPC is incurable and can develop drug resistance.

**Understanding the mechanisms of resistance can enable the development of new-generation therapies for CRPC[2].**

1. www.clinicaltrials.gov
2. Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019 Sep;37(3):288-295

# Recursion Pharmaceuticals


- **Clinical-stage biotechnology company** leveraging technology, including machine learning and AI, to industrialise drug discovery
- **Five research programmes in clinical development**, with a further two in preclinical development and 12 in early discovery
- Agreement signed in September 2024 for a **pilot study fully funded by Recursion**
- ANGLE's **fourth services agreement for 2024** which further builds on the expansion of our large pharma services business

# Other biopharma customers




# NuProbe: NGS pan-cancer gene panel

- Cutting-edge genomics and molecular diagnostics company
- **Option to exclusive global licence** (outside of China) to proprietary pan-cancer NGS panel
- Enables analysis of CTCs and **dual analysis of CTCs and ctDNA from a single blood tube**
- Low-cost, highly sensitive and specific detection of **over 6,500 DNA mutations in 61 clinically relevant genes**
- Highly successful pilot study in breast, lung and ovarian cancers, with more mutations identified exclusively in CTCs, as compared to ctDNA alone

"**CTCs represent a transformative biomarker** in precision oncology, offering extraordinary opportunities to translate scientific discoveries into tangible improvements in patient care…

…**The full potential of liquid biopsy can only be achieved with multi-analyte assessment.**[1]."

Weill Cornell Medicine

**Prof. Massimo Cristofanilli**

**Weill Cornell Medicine, Englander Institute for Precision Medicine, New York Presbyterian Hospital, New York, US**

1. Reduzzi C. et al. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors. Critical Reviews in Oncology/Hematology, (2024) Volume 203, 10.1016/j.critrevonc.2024.104483

# Growing body of third-party evidence

- **FDA and EU clearance** expected to give ANGLE **first mover advantage** in non-invasive repeat testing of intact cancer cells
- **>260** Parsortix systems in use
- **>224,000** Parsortix samples processed at 30 June 2024




Cumulative samples processed at 30 June 2024

As of September 2024

**Clinically relevant biomarkers including:**

EGFR
BRAF
KRAS
PD-L1
HER2
TP53
AR
AR-V7
PIK3CA
DLL3

**# of publications by cancer type: top 6**

| | |
|---|---|
| Breast | 37 |
| Lung | 27 |
| Prostate | 15 |
| Melanoma | 8 |
| Head and neck | 6 |
| Ovarian | 6 |

**100** Peer-reviewed journal publications

**88%** published in high impact journals*

**42** independent centers in 15 countries

**Complete picture** DNA, RNA & proteins

**2nd** most published CTC system in last 5 years

**14** studies demonstrating superiority to other methods

**24** cancer types representing 90% of solid tumours

More than **4,100** patient samples processed

**40** publications studying clinically relevant biomarkers

**Variety of downstream analysis techniques:**

RT-qPCR
dPCR and ddPCR
RNAseq
Immunofluorescence
NGS/TGS
WGA, WES and WTA
Mass Spectrometry

* High impact journals defined as those in quartile 1 and 2 by impact factor

# Outlook

- Good progress with existing **three large pharma contracts with future revenue growth potential**
- **Multiple cross-sell opportunities** with existing large pharma customers
- **Multiple additional large pharma** and corporate contracts under discussion
- **Molecular assay for dual analysis of CTCs and ctDNA** from a single blood sample to be launched within six months
- **Prioritising investment in the growth of the large pharma strategy** to maximise ANGLE's commercial opportunity
- Combined with a reduced cost base, the Company anticipates cashflow positive trading in the second half of 2026 and is **funded to execute on this plan**

**ANGLE plc**

10 Nugent Road
Surrey Research Park
Guildford GU2 7AF
United Kingdom

**angleplc.com**